Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular characterization of a suspected IMP-type carbapenemase-producing Pseudomonas aeruginosa outbreak reveals two simultaneous outbreaks in a tertiary-care hospital.
Gual-de-Torrella A, López-Causape C, Alejo-Cancho I, Rojo-Molinero E, Sanchez-García G, Cortés-Lara S, Rodríguez Moral MB, Berdonces-Gonzalez P, Lopez de Goikoetxea MJ, Oliver A. Gual-de-Torrella A, et al. Among authors: cortes lara s. Infect Control Hosp Epidemiol. 2023 Nov;44(11):1801-1808. doi: 10.1017/ice.2023.75. Epub 2023 May 4. Infect Control Hosp Epidemiol. 2023. PMID: 37138359
Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.
Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, López-Causapé C, Sánchez-Diener I, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas study Group. Del Barrio-Tofiño E, et al. Among authors: cortes lara s. J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835. doi: 10.1093/jac/dkz147. J Antimicrob Chemother. 2019. PMID: 30989186
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
Del Barrio-Tofiño E, Sánchez-Diener I, Zamorano L, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI. Del Barrio-Tofiño E, et al. Among authors: cortes lara s. J Antimicrob Chemother. 2019 Nov 1;74(11):3217-3220. doi: 10.1093/jac/dkz346. J Antimicrob Chemother. 2019. PMID: 31430372 Free article.
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Fraile-Ribot PA, et al. Among authors: cortes lara s. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19. doi: 10.1128/AAC.02165-19. Print 2020 Jan 27. Antimicrob Agents Chemother. 2020. PMID: 31740559 Free PMC article.
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
Gomis-Font MA, Pitart C, Del Barrio-Tofiño E, Zboromyrska Y, Cortes-Lara S, Mulet X, Marco F, Vila J, López-Causapé C, Oliver A. Gomis-Font MA, et al. Among authors: cortes lara s. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0008921. doi: 10.1128/AAC.00089-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34060900 Free PMC article.
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
Barceló I, Cabot G, Palwe S, Joshi P, Takalkar S, Periasamy H, Cortés-Lara S, Zamorano L, Sánchez-Diener I, Moya B, Bhagwat S, Patel M, Oliver A. Barceló I, et al. Among authors: cortes lara s. J Antimicrob Chemother. 2021 Sep 15;76(10):2546-2557. doi: 10.1093/jac/dkab213. J Antimicrob Chemother. 2021. PMID: 34219168
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial.
Torrens G, van der Schalk TE, Cortes-Lara S, Timbermont L, Del Barrio-Tofiño E, Xavier BB, Zamorano L, Lammens C, Ali O, Ruzin A, Goossens H, Kumar-Singh S, Kluytmans J, Paling F, MacLean RC, Köhler T, López-Causapé C, Malhotra-Kumar S, Oliver A; ASPIRE-ICU study team. Torrens G, et al. Among authors: cortes lara s. J Antimicrob Chemother. 2022 Jun 29;77(7):1862-1872. doi: 10.1093/jac/dkac122. J Antimicrob Chemother. 2022. PMID: 35451008 Clinical Trial.
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA, López-Causapé C, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A, Landersdorfer CB. Agyeman AA, et al. Among authors: cortes lara s. Int J Antimicrob Agents. 2023 Sep;62(3):106887. doi: 10.1016/j.ijantimicag.2023.106887. Epub 2023 Jun 12. Int J Antimicrob Agents. 2023. PMID: 37315906
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Among authors: cortes lara s. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
11 results